Literature DB >> 20547766

c-Src-mediated phosphorylation of thyroid hormone receptor-interacting protein 6 (TRIP6) promotes osteoclast sealing zone formation.

Brooke K McMichael1, Stephanie M Meyer, Beth S Lee.   

Abstract

Osteoclasts resorb bone through the formation of a unique attachment structure called the sealing zone. In this study, a role for thyroid hormone receptor-interacting protein 6 (TRIP6) in sealing zone formation and osteoclast activity was examined. TRIP6 was shown to reside in the sealing zone through its association with tropomyosin 4, an actin-binding protein that regulates sealing dimensions and bone resorptive capacity. Suppression of TRIP6 in mature osteoclasts by RNA interference altered sealing zone dimensions and inhibited bone resorption, whereas overexpression of TRIP6 increased the sealing zone perimeter and enhanced bone resorption. Treatment of osteoclasts with lysophosphatidic acid (LPA), which phosphorylates TRIP6 at tyrosine 55 through a c-Src-dependent mechanism, caused increased association of TRIP6 with the sealing zone, as did overexpression of a TRIP6 cDNA bearing a phosphomimetic mutation at tyrosine 55. Further, LPA treatment caused increases in osteoclast fusion, sealing zone perimeter, and bone resorptive capacity. In contrast, overexpression of TRIP6 containing a nonphosphorylatable amino acid residue at position 55 severely diminished sealing zone formation and bone resorption and suppressed the effects of LPA on the cytoskeleton. LPA effects were mediated through its receptor isoform LPA(2), as indicated by treatments with receptor-specific agonists and antagonists. Thus, these studies suggest that TRIP6 is a critical downstream regulator of c-Src signaling and that its phosphorylation is permissive for its presence in the sealing zone where it plays a positive role in osteoclast bone resorptive capacity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20547766      PMCID: PMC2924104          DOI: 10.1074/jbc.M110.119909

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  LIM domain protein Trip6 has a conserved nuclear export signal, nuclear targeting sequences, and multiple transactivation domains.

Authors:  Y Wang; T D Gilmore
Journal:  Biochim Biophys Acta       Date:  2001-04-23

2.  Podosomes display actin turnover and dynamic self-organization in osteoclasts expressing actin-green fluorescent protein.

Authors:  Olivier Destaing; Frédéric Saltel; Jean-Christophe Géminard; Pierre Jurdic; Frédéric Bard
Journal:  Mol Biol Cell       Date:  2003-02       Impact factor: 4.138

3.  Differential localization of myosin II isoforms in resting and activated osteoclasts.

Authors:  I Krits; R B Wysolmerski; L S Holliday; B S Lee
Journal:  Calcif Tissue Int       Date:  2002-09-18       Impact factor: 4.333

4.  Vacuolar H+-ATPase activity and expression in mouse bone marrow cultures.

Authors:  B S Lee; L S Holliday; I Krits; S L Gluck
Journal:  J Bone Miner Res       Date:  1999-12       Impact factor: 6.741

5.  Members of the Zyxin family of LIM proteins interact with members of the p130Cas family of signal transducers.

Authors:  Jinseong Yi; Susanne Kloeker; Christopher C Jensen; Susanne Bockholt; Hiroaki Honda; Hisamura Hirai; Mary C Beckerle
Journal:  J Biol Chem       Date:  2002-01-08       Impact factor: 5.157

Review 6.  Zyxin and paxillin proteins: focal adhesion plaque LIM domain proteins go nuclear.

Authors:  Yuan Wang; Thomas D Gilmore
Journal:  Biochim Biophys Acta       Date:  2003-02-17

Review 7.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

8.  TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor.

Authors:  Jun Xu; Yun-Ju Lai; Weei-Chin Lin; Fang-Tsyr Lin
Journal:  J Biol Chem       Date:  2003-12-18       Impact factor: 5.157

9.  Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.

Authors:  Marion David; Estelle Wannecq; Françoise Descotes; Silvia Jansen; Blandine Deux; Johnny Ribeiro; Claire-Marie Serre; Sandra Grès; Nathalie Bendriss-Vermare; Mathieu Bollen; Simone Saez; Junken Aoki; Jean-Sébastien Saulnier-Blache; Philippe Clézardin; Olivier Peyruchaud
Journal:  PLoS One       Date:  2010-03-17       Impact factor: 3.240

Review 10.  The emerging role of lysophosphatidic acid in cancer.

Authors:  Gordon B Mills; Wouter H Moolenaar
Journal:  Nat Rev Cancer       Date:  2003-08       Impact factor: 60.716

View more
  10 in total

1.  Lysophosphatidic acid stimulates osteoclast fusion through OC-STAMP and P2X7 receptor signaling.

Authors:  Young Sun Hwang; Gwang-Taek Ma; Kwang-Kyun Park; Won-Yoon Chung
Journal:  J Bone Miner Metab       Date:  2013-04-27       Impact factor: 2.626

2.  Osteoclast-Derived Autotaxin, a Distinguishing Factor for Inflammatory Bone Loss.

Authors:  Sacha Flammier; Olivier Peyruchaud; Fanny Bourguillault; François Duboeuf; Jean-Luc Davignon; Derek D Norman; Sylvie Isaac; Hubert Marotte; Gabor Tigyi; Irma Machuca-Gayet; Fabienne Coury
Journal:  Arthritis Rheumatol       Date:  2019-09-30       Impact factor: 10.995

Review 3.  TRIP6: an adaptor protein that regulates cell motility, antiapoptotic signaling and transcriptional activity.

Authors:  Victor T G Lin; Fang-Tsyr Lin
Journal:  Cell Signal       Date:  2011-06-13       Impact factor: 4.315

Review 4.  [Research progress on the biological regulatory function of lysophosphatidic acid in bone tissue cells].

Authors:  Xiang-Nan Wu; Yuan-Yuan Ma; Zhi-Chao Hao; Hang Wang
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-06-01

Review 5.  Osteoblast-osteoclast interactions.

Authors:  Xiao Chen; Zhongqiu Wang; Na Duan; Guoying Zhu; Edward M Schwarz; Chao Xie
Journal:  Connect Tissue Res       Date:  2017-03-21       Impact factor: 3.417

6.  Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity.

Authors:  Marion David; Irma Machuca-Gayet; Junichi Kikuta; Penelope Ottewell; Fuka Mima; Raphael Leblanc; Edith Bonnelye; Johnny Ribeiro; Ingunn Holen; Rùben Lopez Vales; Pierre Jurdic; Jerold Chun; Philippe Clézardin; Masaru Ishii; Olivier Peyruchaud
Journal:  J Biol Chem       Date:  2014-01-15       Impact factor: 5.157

7.  LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption.

Authors:  Jian Luo; Zhengfeng Yang; Yu Ma; Zhiying Yue; Hongyu Lin; Guojun Qu; Jinping Huang; Wentao Dai; Chenghai Li; Chunbing Zheng; Leqin Xu; Huaqing Chen; Jiqiu Wang; Dali Li; Stefan Siwko; Josef M Penninger; Guang Ning; Jianru Xiao; Mingyao Liu
Journal:  Nat Med       Date:  2016-04-11       Impact factor: 53.440

Review 8.  Autotaxin/Lysophosphatidic Acid Axis: From Bone Biology to Bone Disorders.

Authors:  Candide Alioli; Léa Demesmay; Olivier Peyruchaud; Irma Machuca-Gayet
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

9.  The RhoGAP activity of myosin IXB is critical for osteoclast podosome patterning, motility, and resorptive capacity.

Authors:  Brooke K McMichael; Katharine F Scherer; Nicole C Franklin; Beth S Lee
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

Review 10.  Recent Advances in Osteoclast Biological Behavior.

Authors:  Yang Sun; Jiangbi Li; Xiaoping Xie; Feng Gu; Zhenjiang Sui; Ke Zhang; Tiecheng Yu
Journal:  Front Cell Dev Biol       Date:  2021-12-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.